人类免疫缺陷病毒/艾滋病相关弥漫大B细胞淋巴瘤的研究现状  

Current research status of human immunodefieiency virus/acquired immunodeficiency syndrome-related diffuse large B-cell lymphoma

作　　者：白洋禄 邹文蓉[1] 彭鹏[1] Bai Yanglu;Zou Wenrong;Peng Peng(Department of Hematology,Sichuan Mianyang 404 Hospital,Mianyang 621000,Sichuan Province,China)

机构地区：[1]四川绵阳四0四医院血液科,621000

出　　处：《国际输血及血液学杂志》2020年第2期109-113,共5页International Journal of Blood Transfusion and Hematology

基　　金：四川省医学会资助项目(S17058);绵阳市卫生健康委员会资助项目(201745)。

摘　　要：随着抗逆转录病毒联合治疗(cART)的应用,艾滋病相关淋巴瘤(ARL)的发生风险有所下降,但是其仍是最常见艾滋病(AIDS)相关肿瘤,其中基本以B细胞来源为主。人类免疫缺陷病毒(HIV)/AIDS相关弥漫大B细胞淋巴瘤(HIV/AIDS-DLBCL)是其中发病率最高的亚型,临床表现可伴有B症状及结外器官受累等特点。cART联合利妥昔单抗的化疗方案能够显著提高HIV/AIDS-DLBCL患者对化疗的耐受性,并且改善患者预后。笔者拟就HIV/AIDS-DLBCL的流行病学、发病机制及治疗策略进行介绍,旨在进一步加深临床医师对于HIV/AIDS-DLBCL的认识。With the application of antiretroviral combination therapy(cART),the risk of acquired immunodeficiency syndrome-related lymphoma(ARL)has decreased,but it is still the most common acquired immunodeficiency syndrome(AIDS)-related tumor,in which B cells are the primary source.Human immunodefieiency virus(HIV)/AIDS-related diffuse large B-cell lymphoma(HIV/AIDS-DLBCL)is a subtype with the highest incidence,which is clinically associated with B-symptoms and involvement of extratodal organs.Chemotherapy regimen of cART combined with rituximab can significantly improve the chemotherapy tolerance and prognosis of patients with HIV/AIDS-DLBCL.This article discusses the epidemiology,pathogenesis and treatment strategies of HIV/AIDS-DLBCL,so as to further deepen clinicians′understanding of HIV/AIDS-DLBCL.

关 键 词：淋巴瘤 艾滋病相关 获得性免疫缺陷综合征 淋巴瘤 大B-细胞 弥漫性 抗HIV药 抗逆转录病毒治疗 高效 利妥昔单抗 

分 类 号：R733[医药卫生—肿瘤] R51[医药卫生—临床医学]